<DOC>
	<DOCNO>NCT01821040</DOCNO>
	<brief_summary>The study compare efficacy safety modify release prednisone versus immediate release prednisone patient suffer polymyalgia rheumatica .</brief_summary>
	<brief_title>A Study Assessing Efficacy Safety Lodotra® Compared Prednisone IR Subjects Suffering From PMR</brief_title>
	<detailed_description>The study consist screen phase , follow 4 week double-blind phase . During double-blind phase , patient randomise 1:1 ratio either Lodotra® immediate release prednisone ( prednisone IR ) plus respective placebo . After completion double-blind phase , patient re-randomised 1:1 ratio open-label Lodotra® prednisone IR 48 week . During open-label phase , dose study medication taper base titration criterion .</detailed_description>
	<mesh_term>Polymyalgia Rheumatica</mesh_term>
	<mesh_term>Giant Cell Arteritis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Males female , 50 year age old provide write informed consent . 2 . Females less one year postmenopausal must negative serum urine pregnancy test record prior first dose study medication , nonlactating , willing use adequate highly effective method contraception throughout study . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly sterilisation , implant , injectables , combine oral contraceptive , IUDs ( Intrauterine Device , hormonal ) , sexual abstinence vasectomise partner ) . 3 . Subjects newly diagnose polymyalgia rheumatica previously untreated glucocorticoid PMR . The diagnosis polymyalgia rheumatica must confirm follow criterion : New onset bilateral shoulder pain new onset bilateral shoulder hip girdle pain . PMR VAS score last 24 hour Screening Visit ≥ 50 ( 0 100 scale ) . Morning stiffness duration ≥ 45 min day Screening Visit . Acute phase response show elevated Creactive protein ( CRP ; ≥ 2 time ULN ) . 4 . Subjects willing able participate aspect study comply use study medication . 1 . Females pregnant ( positive βhCG test ) lactating . 2 . Subjects contraindication/history hypersensitivity predniso ( lo ) ne ingredient . 3 . Significant renal impairment ( serume creatinine &gt; 150 µmol/L ) . 4 . Significant hepatic impairment ( ALT , AST GGT &gt; 2.5 ULN ) . 5 . Subjects suffer another disease require glucocorticosteroid treatment . Topical glucocorticosteroids , e.g . intranasal inhaled glucocorticosteroids allow kept stable dose throughout study . 6 . Continued use systemic glucocorticoid within 4 week prior Screening Visit . 7 . Joint injection glucocorticoid within 6 week prior Screening Visit . 8 . Subjects require treatment nonpermitted concomitant therapy . 9 . Evidence clinically significant cardiovascular , renal , hepatic , gastrointestinal psychiatric disease time screening , determine medical history , clinical laboratory test , ECG result , physical examination , would place subject risk upon exposure study medication may confound analysis and/or interpretation study result . 10 . Active alcohol drug abuse . 11 . Subjects suffer giant cell arteritis , late onset rheumatoid arthritis inflammatory rheumatoid disease . 12 . Subjects suffer druginduced myalgia . 13 . Subjects suffer fibromyalgia 14 . Subjects suffer systemic lupus erythemathosus . 15 . Subjects suffer neurological condition , e.g . Parkinson 's disease . 16 . Subjects suffer active cancer . 17 . Subjects suffer active infection . 18 . Subjects participate clinical research study involve new chemical entity experimental drug within 30 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Polymyalgia rheumatica</keyword>
	<keyword>PMR</keyword>
	<keyword>Modified release prednisone</keyword>
</DOC>